Abstract: An object is to provide a magnetic sensor module reducing influence of heat generated from a coil on a magnetic sensor. A conventional method requires, on a magnetic sensor chip, multiple temperature measuring circuits corresponding to multiple magnetic sensors, and many pads for connection to an IC chip. Therefore, the problem is increase in size of the sensor chip mounting the sensors and in manufacturing cost. Provided is a magnetic sensor module comprising an IC chip including a first coil, a first pad connected to one end of the coil, and a second pad to the other end; a magnetic sensor chip disposed on the IC chip's surface, including a first magnetic sensor detecting first axial magnetism; a first external output terminal; a first conductive wire for connecting the first pad and terminal; a second external output terminal; and a second conductive wire for connecting the second pad and terminal.

Abstract: A magnetic sensor device includes a composite chip component, and a sensor chip mounted on the composite chip component. The sensor chip includes a first magnetic sensor, a second magnetic sensor, and a third magnetic sensor that detect components of an external magnetic field that are in directions parallel to an X direction, parallel to a Y direction, and parallel to a Z direction, respectively. The composite chip component includes a first magnetic field generator, a second magnetic field generator, and a third magnetic field generator for generating additional magnetic field components that are in directions parallel to the X direction, parallel to the Y direction, and parallel to the Z direction, respectively.

Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.

Abstract: A magnetic sensor device includes three magnetic sensors for detecting components of an external magnetic field that are in three directions, a magnetic field generation section, and a correction processor. The magnetic field generation section generates additional magnetic field components in three directions used for measurements of main- and cross-axis sensitivities of the three magnetic sensors. The correction processor corrects respective detection signals of the three magnetic sensors on the basis of the measurement results of the main- and cross-axis sensitivities of the magnetic sensors.

Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.

Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.

Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.

Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating chronic kidney disease that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a renal tissue regeneration mechanism by which Muse cells are made to selectively accumulate at a site of kidney disease and differentiate into cells that compose the kidney by administering Muse cells intravenously to a subject having the aforementioned disease.

Abstract: Semiconductor device assemblies with molded support substrates and associated methods are disclosed herein. In one embodiment, a semiconductor device assembly includes a support substrate, a first semiconductor die embedded within the support substrate, a second semiconductor die coupled to the support substrate, and a third semiconductor die coupled to the support substrate. The assembly can also include a redistribution network formed on a first and/or second side of the support substrate, and a plurality of conductive contacts electrically coupled to at least one of the first, second or third semiconductor dies.

Abstract: Semiconductor device assemblies with molded support substrates and associated methods are disclosed herein. In one embodiment, a semiconductor device assembly includes a support substrate formed from a molded material, a first semiconductor die at least partially embedded within the support substrate, a plurality of interconnects extending at least partially through the molded material, a second semiconductor die coupled to the support substrate, and a third semiconductor die coupled to the support substrate. The assembly can also include a redistribution network formed on a first and/or second side of the support substrate, and a plurality of conductive contacts electrically coupled to at least one of the first, second and third semiconductor dies.

Abstract: An ink jet recording method for recording an image on a recording medium by using an aqueous reaction liquid containing a reactant and a first ink and a second ink, each a water-based ink containing a coloring material, includes a reaction liquid applying step, an image formation step for forming a first image by applying the first ink and the second ink in this order to the transfer body so as to overlap at least partially with a region to which the reaction liquid has been applied, a liquid absorption step for bringing a porous layer possessed by a liquid absorption member into contact with the first image to absorb a liquid component therefrom, and after the liquid absorption step, a transfer step for transferring the first image on the transfer body to the recording medium, and the first ink has brightness higher than the brightness of the second ink.

Abstract: Objects of the present invention are to provide a method for directly obtaining pluripotent stern cells which do not have tumorigenic property from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stern cells that can be isolated from body tissue.

Abstract: Semiconductor device assemblies with molded support substrates and associated methods are disclosed herein. In one embodiment, a semiconductor device assembly includes a support substrate formed from a molded material, a first semiconductor die at least partially embedded within the support substrate, a plurality of interconnects extending at least partially through the molded material, a second semiconductor die coupled to the support substrate, and a third semiconductor die coupled to the support substrate. The assembly can also include a redistribution network formed on a first and/or second side of the support substrate, and a plurality of conductive contacts electrically coupled to at least one of the first, second and third semiconductor dies.

Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.

Abstract: A packing box has a bottom panel, end panels raised from first edges of the bottom panel, side panels arranged adjacently to the end panels, edge panels connected to side edges of the end panels via outer panel fold lines, fold-back panels arranged on inner side surfaces of the edge panels, inner panels arranged on inner side surfaces of the end panels, and reinforcing panels continuously formed with the fold-back panels via first fold lines and the inner panels via second fold lines. The reinforcing panel 16 is formed in an inwardly projecting manner between the fold-back panel and the inner panel. Any of the first and second fold lines positioned on a side closer to the outer panel fold line than a projecting top portion is arranged away from the outer panel fold line by a distance.

Abstract: A box includes a front receiving panel, a bottom surface panel, a rear surface panel, a top surface panel, and a front surface panel that are integrally connected one to another. Each pair of bottom side panels, rear side panels, top side panels, and front side panels are integrally connected to the respective sides of each of the bottom, rear, top, and front surface panels. The front receiving panel, the bottom and rear surface panels, and the bottom and rear side panels constitute a tray portion of the box, with the remaining panels constituting a lid portion of the box. A cut line for separating the lid portion from the tray portion is formed to pass through one or both of the rear surface panel and the top surface panel.

Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.

Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.

Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.

Abstract: An aqueous ink for ink jet including a resin particle. The resin particle includes a first layer and a second layer in this order from the inside to the outside thereof. The first layer is composed of a first resin, wherein the proportion of a unit derived from an aromatic-group-containing ethylenically unsaturated monomer in the first resin is 10% by mass or less. The second layer has a tetrahydrofuran-insoluble fraction of 10% by mass or more and is composed of a second resin having a unit derived from an aromatic-group-containing ethylenically unsaturated monomer and a unit derived from an ionic-group-containing ethylenically unsaturated monomer, wherein the proportion of the unit derived from the ionic-group-containing ethylenically unsaturated monomer in the second resin is 3% by mass or more to 70% by mass or less.